Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 132

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 132
---
               |            |   |     | 2023 |            |   |
|:--------------------------------------------------------------------|:----|:-------------------|-----------:|:--|:----|:-----|-----------:|:--|
|                                                                     |     | US$                |            |   |     |      |            |   |
| Net cash used in operating activities                               |     |                    | (8,264,074 | ) |     |      | (1,766,135 | ) |
| Net cash used in investing activities                               |     |                    |    (53,045 | ) |     |      |    (69,848 | ) |
| Net cash provided by financing activities                           |     |                    |  8,675,790 |   |     |      |  1,881,493 |   |
| Net increase in cash and cash equivalents                           |     |                    |    358,671 |   |     |      |     45,510 |   |
| Effect of foreign currency translation on cash and cash equivalents |     |                    |     44,965 |   |     |      |    (18,962 | ) |
| Cash and cash equivalents, beginning of year                        |     |                    |     54,104 |   |     |      |     27,556 |   |
| Cash and cash equivalents, end of year                              |     |                    |    457,740 |   |     |      |     54,104 |   |

<div align='center'>77</div>

Operating activities

Net cash used in operating
activities was US$8,264,074 for the year ended December 31, 2024. The difference between NewGenIvf’s net loss of US$474,101
for the year ended December 31, 2024 and the net cash used in operating activities was primarily attributable to (i) an increase
of agent’s receivable of US$1,191,795, (ii) a cash deposit of US$1,000,000 with a digital trading platform and settlement of
charges in relation to the de-spac and business reorganisation.

Net cash used in operating
activities was US$1,766,135 for the year ended December 31, 2023. The difference between NewGenIvf’s net profit of US$108,418 for
the year ended December 31, 2023 and the net cash used in operating activities was primarily